• Journal of Chest Surgery
• /
• v.3 no.2
• /
• pp.143-148
• /
• 1970

Bleomycin is known as a antibiotic agent for malignant tumors especially sguamous cell carcinoma. We have treated 2 cases of malignant tumors, each one esophageal and lung carcinoma with bleomycin, 630 mg and 510 mg respectively. In case of esophageal carcinoma. the subjective symptoms such as dysphagea and swallowing disturbance are temporally relieved, but the irregular filling defect is not significantly changed in esophagogram. In case of lung carcinoma, the atelectasis of right upper lobe on chest X-ray was slightly regressed in its size without effective improvement of subjective symptoms. However, following additional radioactive $^60{Co}$ irradiation therapy (5200r), marked regression of tumor density and aeration of right upper lobe was observed. But 2 weeks later of ceasatioil of irradiatio:J, atelectasis of right upper lobe was again developed. Fever, anorexia, headache and eruption were developed during the treatmeat with bleomycin in both cases but the sign or symptoms of hone marrow depression, renal or liver damage were not noted.

• Progress in Medical Physics
• /
• v.6 no.2
• /
• pp.21-28
• /
• 1995

In recent years there has been a growing interest in total body irradiation. For refractory leukemia or lymphoma patients, varions techniques and dose regimens were intridused, including high dose total body irradiation for destruction of leukemic or bone marrow cells and immunosupperression prior to bone marrow transplantation. Accurate provision for specified dose and the desired homogeneity are essential before clinical total body irradiatio. When performed in total body irradiation, the problem obtain uniform uniform dose distribution in brain, neck, lung, umbilicus, pelvis and leg. Authors compared to dose distribution with method 1 and method 1. The method 1 used compensationg filters for homogeneous dose distribution(Minesota University Method). The method 2 used fixing frame made in acryl developing authors. Results were following 1. Method 1 was showed dose distribution from 95.6％ to 100％, method 2 showed dose distribution from 95.4％ to 100％ 2. Method 2 was showed different to 3.4％ at skin region and midline in the brain. In the neck, showed different to 1.5％. In the umbilicus, showed different to 2.3％.

• Radiation Oncology Journal
• /
• v.28 no.3
• /
• pp.133-140
• /
• 2010

Purpose: We retrospectively investigated the effect of irradiation using helical tomotherapy in recurrent pelvic tumors that underwent prior irradiation. Materials and Methods: Fourteen patients with recurrent pelvic tumors consisting of rectal cancer (57.1%), cervical cancer (35.7%) and cancer with an unknown origin (7.1%) were treated with tomotherapy. At the time of irradiation, median tumor size was 3.5 cm and 7 patients complained of pain originating from a recurrent tumor. The median radiation dose delivered to the gross tumor volume, clinical target volume, and planning target volume was 50 Gy, 47.8 Gy and 45 Gy, respectively and delivered at 5 fractions per week over the course of 4 to 5 weeks. Treatment response and duration of local disease control were evaluated using the Response Evaluation Criteria in Solid Tumors (ver. 1.0) and the Kaplan-Meyer method. Treatment-related toxicities were assessed through Common Terminology Criteria for Adverse Events (ver. 3.0). Results: The median follow-up time was 17.3 months, while the response rate was 64.3%. Symptomatic improvement appeared in 6 patients (85.7%). The median duration time of local disease control was 25.8 months. The rates of local failure, distant failure, and synchronous local and distant failure were 57.1%, 21.4%, and 7.1%, respectively. Acute toxicities were limited in grade I or II toxicities, except for one patient. No treatment related death or late toxicity was observed. Conclusion: Helical tomotherapy could be suggested as a feasible palliative option in recurrent pelvic tumors with prior radiotherapy. However, to increase treatment effect and overcome the limitation of this outcome, a large clinical study should be performed.